The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Non-HLA-matched pooled umbilical cord blood transplant in acute leukemias and MDS
Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the results of a study investigating non-HLA-matched pooled umbilical cord blood transplantation in patients with acute leukemias or myelodysplastic syndromes (MDS) in complete remission. Dr Milano highlights the encouraging outcomes with this approach, with an overall survival (OS) of 96% reported in this cohort. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Okay, so about the study with non-HLA matched pool donor, we are describing a study that has been concluded in Seattle at the Fred Hutchinson Cancer Research Center, where basically we use pooled cord blood units and expand them and put them as off-the-shelf. We then pair this unit along with a matched cord blood unit for patients undergoing cord blood transplantation...
Okay, so about the study with non-HLA matched pool donor, we are describing a study that has been concluded in Seattle at the Fred Hutchinson Cancer Research Center, where basically we use pooled cord blood units and expand them and put them as off-the-shelf. We then pair this unit along with a matched cord blood unit for patients undergoing cord blood transplantation. We have enrolled 28 patients, and I’m pleased to report that we have an outstanding overall survival of 96% with a 0% grade 3 and 4 GVHD and 0% chronic GVHD. Basically, the non-HLA-matched pool donor is working as a decoy for the HLA-matched unit, and doing that increases the graft-versus-leukemia effect, that’s our hypothesis, and at the same time makes the unit tolerant towards the host, and that’s why we think we saw a very low rate of acute and chronic GVHD.
In the study that we recently conducted, we enrolled mainly patients with acute leukemias, both acute myeloid leukemias and acute lymphoblastic leukemias. We also had patients with myelodysplastic syndrome. And basically, this is the majority of patients undergoing transplantations anyway. And the other thing that I can add in this specific clinical trial, we only allowed patients who were in complete remission, which means basically patients with potentially minimal residual disease or less than 5% blasts undergoing a cord blood transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
